89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
89bio (Nasdaq: ETNB) announced that its Compensation Committee approved an inducement grant of non-qualified stock options to one new employee. The grant, made under the company's 2023 Inducement Plan, allows for the purchase of 48,000 shares of common stock at an exercise price equal to the closing price on December 13, 2024. The options will vest over four years, with 25% vesting after one year and the remaining portion vesting in 12 equal quarterly installments, contingent on continued employment.
89bio (Nasdaq: ETNB) ha annunciato che il suo Comitato Compensi ha approvato un'indennità di opzioni su azioni non qualificate per un nuovo dipendente. L'indennità, effettuata nell'ambito del Piano di Induzione 2023 dell'azienda, consente l'acquisto di 48.000 azioni ordinarie a un prezzo di esercizio uguale al prezzo di chiusura del 13 dicembre 2024. Le opzioni matureranno nel corso di quattro anni, con il 25% che matura dopo un anno e la parte rimanente che matura in 12 rate trimestrali uguali, a condizione della continuazione del rapporto di lavoro.
89bio (Nasdaq: ETNB) anunció que su Comité de Compensación aprobó una concesión de opciones sobre acciones no calificadas para un nuevo empleado. La concesión, realizada bajo el Plan de Inducción 2023 de la compañía, permite la compra de 48,000 acciones comunes a un precio de ejercicio igual al precio de cierre del 13 de diciembre de 2024. Las opciones se consolidarán durante cuatro años, con el 25% consolidándose después de un año y la parte restante consolidándose en 12 cuotas trimestrales iguales, condicionadas a la continuidad del empleo.
89bio (Nasdaq: ETNB)는 보상위원회가 새로운 직원에게 비상장 주식 옵션의 유인 보상을 승인했다고 발표했습니다. 이 보상은 회사의 2023 유인 계획에 따라 이루어지며, 2024년 12월 13일의 종가와 동일한 행사 가격으로 48,000주의 보통주를 구매할 수 있습니다. 옵션은 4년에 걸쳐 부여되며, 1년 후 25%가 부여되고 나머지 부분은 계속적인 고용 조건에 따라 12개의 동등한 분기별 할부로 부여됩니다.
89bio (Nasdaq: ETNB) a annoncé que son Comité de Rémunération a approuvé une attribution d'options sur actions non qualifiées pour un nouvel employé. L'attribution, faite dans le cadre du Plan d'Induction 2023 de la société, permet l'achat de 48 000 actions ordinaires à un prix d'exercice égal au prix de clôture du 13 décembre 2024. Les options seront acquises sur quatre ans, avec 25 % acquises après un an et le reste acquis en 12 versements trimestriels égaux, sous réserve de la poursuite de l'emploi.
89bio (Nasdaq: ETNB) gab bekannt, dass der Vergütungsausschuss eine Induktionsgewährung von nicht qualifizierten Aktienoptionen an einen neuen Mitarbeiter genehmigt hat. Die Gewährung, die im Rahmen des Unternehmensplans zur Induktion 2023 erfolgt, erlaubt den Kauf von 48.000 Aktien zu einem Ausübungspreis, der dem Schlusskurs vom 13. Dezember 2024 entspricht. Die Optionen werden über vier Jahre fällig, wobei 25% nach einem Jahr fällig werden und der Rest in 12 gleichen vierteljährlichen Raten fällig wird, vorausgesetzt, die Anstellung bleibt bestehen.
- None.
- None.
SAN FRANCISCO, Dec. 19, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the Compensation Committee of the Company’s Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 48,000 shares of the Company’s common stock to one new employee (the “Inducement Grant”) on December 13, 2024 (the “Grant Date”). The Inducement Grant has been granted pursuant to the Company’s 2023 Inducement Plan (the “Plan”). The Inducement Grant was granted as an inducement material to the individual entering into employment with 89bio in accordance with Nasdaq Listing Rule 5635(c)(4).
The Inducement Grant has an exercise price per share that is equal to the closing price of 89bio’s common stock on the Grant Date. The Inducement Grant will vest over a four-year period, with
About 89bio
89bio is a clinical-stage biopharmaceutical company dedicated to the development of best-in-class therapies for patients with liver and cardiometabolic diseases who lack optimal treatment options. The company is focused on rapidly advancing its lead candidate, pegozafermin, through Phase 3 clinical development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and severe hypertriglyceridemia (SHTG). Pegozafermin is a specifically engineered, potentially best-in-class fibroblast growth factor 21 (FGF21) analog with unique glycoPEGylated technology that optimizes biological activity through an extended half-life. The company is headquartered in San Francisco. For more information, visit www.89bio.com or follow the company on LinkedIn.
Investor Contact:
Annie Chang
89bio, Inc.
investors@89bio.com
PJ Kelleher
LifeSci Advisors, LLC
+1-617-430-7579
pkelleher@lifesciadvisors.com
Media Contact:
Sheryl Seapy
Real Chemistry
sseapy@realchemistry.com
FAQ
How many shares are included in 89bio's (ETNB) December 2024 inducement grant?
What is the vesting schedule for 89bio's (ETNB) December 2024 inducement grant?
What is the exercise price for 89bio's (ETNB) December 2024 inducement options?
Under which plan were 89bio's (ETNB) December 2024 inducement options granted?
